Featured Story

  • The White House draws the line against CRISPR/Cas9-designed embryos

    Fretting over the implications of reengineering human embryos with new CRISPR/Cas9 gene editing technology, officials at the White House have weighed in to the growing controversy, saying that "altering the human germline for clinical purposes is a line that should not be crossed at this time."

Thunder god vine compound may have potent anti-obesity characteristics

Bariatric surgery remains the only effective solution for many to reduce body weight and improve associated comorbidities. Now researchers at Harvard Medical School see some real potential in a recently isolated extract, celastrol, found in the roots of the thunder god vine (Tripterygium wilfordii) used in traditional Chinese medicine.

Winship research team flags potential of a new lung cancer therapy

Investigators at the Winship Cancer Institute at Emory University say they've found a new molecule that appeared to do better than an inhibitor in preclinical in vivo testing.

Pitt team unveils two new classes of RNAs for cancer drug R&D

Investigators at the University of Pittsburgh School of Medicine says they have ID'd two new classes of RNAs that could play a significant role in cancer drug R&D.

Scientists leverage cell stress to defeat cancer drug resistance

Scientists from Cincinnati Children's Hospital Medical Center report that the best way to prevent breast cancer from growing resistant to therapies may be to genetically strip cancer cells' natural defenses against intrinsic stress.

UIC team spurs fresh hope for an islet-cell cure for Type 1 diabetes

Researchers have been experimenting with islet cell transplantation as a possible cure for Type 1 diabetes for decades. These insulin-producing cells are destroyed by Type 1 diabetes, but various transplant methods that worked in animals--including using tiny capsules to deliver the cells in a way that guards against an immune response--have failed to make the grade in humans.


From Our Sister Sites


Bavarian Nordic has downplayed its interest in becoming the latest European biotech to be scooped up by a deep-pocketed suitor. The vaccine player has regained some of its luster over the past year through deals with Bristol-Myers Squibb and Johnson & Johnson, but has no desire to cash in on its moment in the limelight.


U.K. CRO Ergomed is expanding its share of the postmarketing services business, buying a medical information firm that fields patient queries for drug companies.